Retatrutide helped trial participants lose up to 28.7% of their body weight, but experts warn about excessive weight loss.

News and commentary from the endocrinology world ...

Too much of a good thing? Participants taking the highest dose of Eli Lilly’s new GLP-1 drug lost an average of 28.7% of their body weight in a late-stage trial, putting it on track to be a ...

Some patients in a clinical trial of one new drug lost so much weight that they became concerned and dropped out.

Obesity has emerged as one of the most significant yet preventable risk factors for ovarian cancer, often called the silent ...

Some GLP-1 patients are begging to stay on the drugs just a little bit longer, presenting an ethical dilemma for doctors.

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Eli Lilly’s ...

You might notice that, shortly after you’ve consumed something high in sugar, you experience what’s commonly known as a ...